Phosphatidylglycerol suppresses influenza A virus infection

American Journal of Respiratory Cell and Molecular Biology

Volumn 46, Issue 4, 2012, Pages 479-487

  Numata, Mari ^a   Kandasamy, Pitchaimani ^a   Nagashima, Yoji ^b   Posey, Janelle ^a   Hartshorn, Kevan ^c   Woodland, David ^d   Voelker, Dennis R ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TRUDEAU INSTITUTE   (United States)

Author keywords

Antiviral; Innate immunity; Pulmonary surfactant

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; INTERLEUKIN 8; LUNG SURFACTANT; PALMITOYL OLEOYL PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS MUCOSA; CELL CULTURE; CELL DEATH; CELL DIVISION; CELL INFILTRATION; CELL MEMBRANE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; INFLUENZA A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INOCULATION; KIDNEY CELL; KIDNEY CELL CULTURE; LUNG LAVAGE; MOUSE; NONHUMAN; VIRUS ATTACHMENT; VIRUS REPLICATION; VIRUS STRAIN;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; BRONCHI; CELL DEATH; CELLS, CULTURED; CYTOKINES; EPITHELIAL CELLS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PHOSPHATIDYLGLYCEROLS; PHOSPHOLIPIDS; VIRAL PROTEINS; VIRUS REPLICATION;

INFLUENZA A VIRUS; MUS;

EID: 84859411162     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0194OC     Document Type: Article

References (31)

1. Glezen WP. Clinical practice: prevention and treatment of seasonal influenza. N Engl J Med 2008;359:2579-2585.
2. Gooskens J, Jonges M, Claas E, Meijer A, van den Broek P, Kroes A. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A (H1N1) virus. JAMA 2009;301:1066.
3. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003;362: 1733-1745. (Pubitemid 37468326)
4. Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, Krishnan JA. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006; 174:633-638. (Pubitemid 44395329)
5. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy 2009;39:193-202.
6. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-1944.
7. World Health Organization. Seasonal flu. Washington, D.C.: World Health Organization; 2009.
8. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-1373. (Pubitemid 41362704)
9. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009;301:1066-1069.
10. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-765. (Pubitemid 39165094)
11. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St George K, Epperson S, Brammer L, Klimov AI, et al. Infections with oseltamivir-resistant influenza a(H1N1) virus in the United States. JAMA 2009;301:1034-1041.
12. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005;5:58-68. (Pubitemid 40070331)
13. Numata M, Voelker DR. Asthma and infections. In: Martin RJ, Sutherland ER, editors. Lung biology in health and disease. New York: Informa Healthcare; 2010. pp. 45-165.
14. Wright SM, Hockey PM, Enhorning G, Strong P, Reid KB, Holgate ST, Djukanovic R, Postle AD. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol 2000;89:1283-1292.
15. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993;147:218-233. (Pubitemid 23025945)
16. Kuronuma K, Mitsuzawa H, Takeda K, Nishitani C, Chan ED, Kuroki Y, Nakamura M, Voelker DR. Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharideinteracting proteins CD14 and MD-2. J Biol Chem 2009;284: 25488-25500.
17. Wang PY, Kitchens RL, Munford RS. Phosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide. J Biol Chem 1998;273:24309-24313. (Pubitemid 28454917)
18. Hashimoto M, Asai Y, Ogawa T. Treponemal phospholipids inhibit innate immune responses induced by pathogen-associated molecular patterns. J Biol Chem 2003;278:44205-44213. (Pubitemid 37377164)
19. Mueller M, Brandenburg K, Dedrick R, Schromm AB, Seydel U. Phospholipids inhibit lipopolysaccharide (LPS)-induced cell activation: a role for LPS-binding protein. J Immunol 2005;172:1091-1096. (Pubitemid 40094306)
20. Numata M, Chu HW, Dakhama A, Voelker DR. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc Natl Acad Sci USA 2010;107: 320-325.
21. Kandasamy P, Zarini S, Chan ED, Leslie CC, Murphy RC, Voelker DR. Pulmonary surfactant phosphatidylglycerol inhibits Mycoplasma pneumoniae-stimulated eicosanoid production from human and mouse macrophages. J Biol Chem 2011;286:7841-7853.
22. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1:398-401.
23. Daly K, Nguyen P, Woodland DL, Blackman MA. Immunodominance of major histocompatibility complex class I-restricted influenza virus epitopes can be influenced by the T-cell receptor repertoire. J Virol 1995;69:7416-7422.
24. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.
25. Hartshorn KL, White MR, Tecle T, Holmskov U, Crouch EC. Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D. J Immunol 2006;176:6962-6972. (Pubitemid 43791972)
26. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, Suzuki H, Nishimura H, Mitamura K, Sugaya N, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 2004;431:703-707. (Pubitemid 39382618)
27. Cimolai N, Taylor GP, Mah D, Morrison BJ. Definition and application of a histopathological scoring scheme for an animal model of acute mycoplasma pneumoniae pulmonary infection. Microbiol Immunol 1992;36:465-478.
28. Hallman M, Merritt TA, Bry K. The fate of exogenous surfactant in neonates with respiratory distress syndrome. Clin Pharmacokinet 1994;26:215-232. (Pubitemid 24081626)
29. Perino J, Crouzier D, Spehner D, Debouzy JC, Garin D, Crance JM, Favier AL. Lung surfactant DPPG phospholipid inhibits vaccinia virus infection. Antiviral Res 2011;89:89-97.
30. LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T. Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol 2002;282:L563-L572. (Pubitemid 34654662)
31. Hawgood S, Brown C, Edmondson J, Stumbaugh A, Allen L, Goerke J, Clark H, Poulain F. Pulmonary collectins modulate strain-specific influenza A virus infection and host responses. J Virol 2004;78: 8565-8572. (Pubitemid 39025122)